Evidence map›Paper›PMID 39437430›Full record

ArticleJournal of the American Society for Mass Spectrometry2024

Improving Top-Down Sequence Coverage with Targeted Fragment Matching.

Matthew T Robey, Kenneth R Durbin

Abstract read
In one paragraph

Article in Journal of the American Society for Mass Spectrometry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Top-Down and Middle-Down Mass Spectrometry of Antibodies.Molecular & cellular proteomics : MCP · 2025
    Review
  4. A Fast Neural Network for Isotopic Charge State Assignment.Journal of the American Chemical Society · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Matthew T RobeyProteinaceous, Inc., Evanston, Illinois 60208, United States.ORCID 0000-0002-3596-9597
Kenneth R DurbinProteinaceous, Inc., Evanston, Illinois 60208, United States.ORCID 0000-0001-7163-4877

Funding

Data-Driven Software to Automate Top-Down Mass Spectrometry of Large MoleculesR44GM136046 · NIGMS · PROTEINACEOUS, INC. · PI DURBIN, KENNETH · 2023 to 2024
$1.9M
A comprehensive solution for native top down mass spectrometry data analyses across structural biology and biopharmaR44GM130262 · NIGMS · PROTEINACEOUS, INC. · PI DURBIN, KENNETH · 2022 to 2023
$1.6M
NIGMS NIH HHS R44 GM130262NIGMS NIH HHS R44 GM136046
6 · The paper itself

Abstract

Top-down mass spectrometry (TDMS) of intact proteins and antibodies enables direct determination of truncations, sequence variants, post-translational modifications, and disulfides without the need for any proteolytic cleavage. While mass deconvolution of top-down tandem mass spectra is typically used to identify fragment masses for matching to candidate proteoforms, larger molecules such as monoclonal antibodies can produce many fragment ions, making spectral interpretation challenging. Here, we explore an alternative approach for proteoform spectral matching that is better suited for larger protein analysis. This workflow uses direct matching of theoretical proteoform isotopic distributions to TDMS spectra, avoiding drawbacks of mass deconvolution such as poor sensitivity and problems differentiating overlapping distributions. Using a data set that analyzed an intact NIST monoclonal antibody across different fragmentation modes, we show that this isotope fitting strategy increased the sequence coverage of both light and heavy chain sequences >3-fold. We further found that isotope fitting is particularly amenable to identifying large fragments, including those near the hinge region that have been traditionally difficult to analyze by top-down methods. These advances in proteoform spectral matching can greatly increase the power of top-down analyses for intact biotherapeutics and other large molecules.

Indexed as

Antibodies, MonoclonalTandem Mass SpectrometryAmino Acid SequenceHumansPeptide FragmentsSequence Analysis, ProteinAntibodies, MonoclonalPeptide Fragments

Identifiers

PMID39437430
PMCPMC11623164

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.